Description
Introduction:
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Intended Use:
The Enfuvirtide ELISA is used for estimation of Enfuvirtide in serum, plasma, or tissue extracts in pharmacokinetics, peptide delivery study and other purposes.
Principle:
The Enfuvirtide ELISA is a sandwich immunoassay for the determination of Enfuvirtide. The antibodies coated on a 96-well plate capture the standard or sample. Enfuvirtide antiserum is subsequently bound to this complex. Biotin is then added followed by SA-HRP (streptavidin-conjugated horseradish peroxidase), which produces a soluble colored product after a substrate is added. The enzyme reaction is stopped by dispensing an acidic solution (H2SO4) into the wells after 10 min at room temperature turning the solution from blue to yellow. The optical density (OD) of the solution at 450 nm is directly proportional to the amount of specific Enfuvirtide bound.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!